Page URL: https://www.bionews.org.uk/page_136024

Crowdfunding 'misleads' on stem cell treatments

21 May 2018
Appeared in BioNews 950

Crowdfunding campaigns to raise money for stem cell treatments tend to exaggerate potential benefits while understating potential risks of the interventions, suggests a new study.

When insurance companies will not pay for unproven stem cell treatments, patients sometimes seek other sources such as crowdfunding, which harnesses social media to raise money.

In the recent study in JAMA, Dr Jeremy Snyder at the University of Simon Fraser University in Burnaby, Canada, and colleagues concluded that crowdfunding practices might bias public opinion, and place treating clinicians in difficult ethical positions.

'These findings suggest that medical crowdfunding campaigns convey potentially misleading messages about stem cell-based interventions,' they added.

The researchers searched for mentions of businesses offering stem cell interventions on the crowdfunding web sites GoFundMe and YouCaring and identified 408 campaigns seeking funding for stem cell treatments sold by US businesses. Researchers noted that the actual number is likely to be higher as the study only investigated campaigns from 351 businesses and only on two crowdfunding platforms.

In recent years, crowdfunding websites have provided new possibilities for patients to raise money for treatments, including non-established interventions. The claims made by websites are often enhanced by the emotional context provided, including testimonies from patients, said the researchers.

Currently, the only stem cell-based treatments for which there is good evidence for efficacy are blood and immune conditions such as leukemia and grafts used in skin and eye surgeries. While there is progress in research investigating other uses of stem cell treatments, these interventions remain experimental.

Last week, the US FDA (Food and Drug Administration) sought a permanent injunction to close down two clinics offering unapproved stem cell therapies (see BioNews 949). Three patients had lost their eyesight after undergoing experimental stem cell interventions to treat eye conditions at one of the affiliated clinics (see BioNews 893).

'Online crowdsourcing can potentially amplify a false message about access to beneficial stem cell treatments, diverting patients from other forms of evidence-based care,' said stem cell researchers Dr Megan Munsie and Dr Claire Tanner at the University of Melbourne, Australia, in an article for Cosmos.

'Raising awareness of this is critical to avoid the exploitation of not only those seeking treatment, but those generous donors investing in their healthcare,' they said.

SOURCES & REFERENCES
Crowdfunding for Unproven Stem Cell–Based Interventions
JAMA |  8 May 2018
Warning over crowdsourced stem cell schemes
Cosmos |  17 May 2018
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
16 September 2019 - by Jen Willows 
Google has announced a new Healthcare and Medicines policy whereby clinics offering 'unproven or experimental medical techniques' will not be allowed to advertise on the platform...
22 October 2018 - by Ruth Retassie 
Clinicians and researchers have petitioned that a clinical trial for a stem-cell based treatment for heart disease be halted, as some of the results on which it was based have been called into question...
14 May 2018 - by Paul Waldron 
The US Food and Drug Administration is seeking to shut down two clinics offering treatments based on stem cells...
9 April 2018 - by Dr Elizabeth Oliver 
A storage failure at a private UK tissue bank may have resulted in the loss of valuable stem cell samples obtained from newborn babies...
4 September 2017 - by Rikita Patel 
The US Food and Drug Administration intends to investigate the use of unproven stem cell therapies being offered in the country's clinics...
21 September 2015 - by Paul Waldron 
The Food and Drug Administration must do more to control clinics offering unproven stem cell treatments in the USA, say scientists....
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.